Daojing Wang, Ph.D., Founder and CEO, Chairman of the Board
Dr. Wang founded Newomics Inc. in August 2011 while a Career Scientist and Principal Investigator at Lawrence Berkeley National Laboratory (LBNL), where he had worked since 2002. Dr. Wang launched Newomics in September 2013 to further its technology development and commercialization. Dr. Wang has been continuously serving as a principal investigator for multiple research grants from NIH, DOE, NASA, and CBCRP. He has published extensively in highly respected journals such as Aging Cell, Analytical Chemistry, Cancer Research, Journal of Proteome Research, Molecular and Cellular Proteomics, Proceedings of the National Academy of Sciences, Proteomics, and Trends in Biotechnology etc. Dr. Wang is the co-inventor of multiple issued and pending patents including M3 emitters, MEA chips, and senescence chips, which together lay the foundation for Newomics’ platforms and solutions for precision medicine. Prior to joining LBNL, Dr. Wang had performed research at SurroMed Inc. and the University of California, San Francisco. Dr. Wang obtained his B.S. degree from University of Science and Technology of China (USTC) in 1994, Ph.D. in Chemistry from Princeton University in 1999, and completed his postdoctoral training at the University of California, Berkeley in 2000.
Pan Mao, Ph.D., Co-Founder, Board member
Dr. Mao co-founded Newomics Inc. with Dr. Wang in August 2011. Dr. Mao is the co-inventor of M3 emitters and MEA chips. Dr. Mao has extensive experience in developing micro/nanofluidic technologies to solve biological problems. He has made significant contributions to the application of micro/nanofluidics for biological sample preparation and development of fully integrated micro/nanofluidic bioanalytical systems to perform high-throughput omics analysis. Dr. Mao has published over 15 papers in well-respected journals such as Analytical Chemistry, Journal of Proteome Research, and Lab-on-a-Chip, and has served as principal investigator and co-investigator at Newomics Inc. for several NIH SBIR projects. Dr. Mao obtained his B.S. degree from USTC in 2002, Ph.D. in Mechanical Engineering from MIT in 2009, and completed his postdoctoral training at LBNL in 2013.
Patrick J. Scannon, M.D., Ph.D., Board Member
Dr. Scannon has an entrepreneurial background in medicine, having founded a publicly traded biotech company, XOMA Corporation, in 1981. He retired from XOMA in 2016 and currently serves on boards of public, private and not-for-profit organizations and is President of Project Recover, Inc., a not-for-profit organization whose mission is repatriating American MIAs from WWII. Dr. Scannon holds a Ph.D. in organic chemistry from the University of California, Berkeley and an MD from the Medical College of Georgia. He completed his medical internship and residency in internal medicine at the Letterman Army Medical Center in San Francisco. A board-certified internist, Dr. Scannon is also a member of the American College of Physicians. He is the inventor or co-inventor of several issued U.S. patents, and has published numerous scientific abstracts and papers. Dr. Scannon has served as a Trustee of the University of California Berkeley Foundation and as a member of the University of California Berkeley Chancellor’s Community Advisory Board. He has served as a member of the Research Committee for Infectious Diseases Society of America (IDSA), the National Biodefense Science Board (NBSB), a federal advisory board for the Department of Health and Human Services as well as a member of the Defense Sciences Research Council (DSRC), a research board for Defense Advanced Research Projects Agency (DARPA), and the Threat Reduction Advisory Committee for the Department of Defense.
Ted Hou, Ph.D., Board Member
Dr. Hou is the founding partner of Berkeley Catalyst Fund. He started his career in the fiber optic communications industry. For over ten years he managed product marketing and product development and later served as the general manager of the passive component business unit for JDS Uniphase. In 2010, Dr. Hou joined the solar energy industry and served as VP of Marketing at Hanwha SolarOne and VP of Product Strategy at NRG Residential Solar. During this time, Dr. Hou gained experience in solar panel manufacturing, solar farm project financing, and residential solar financing. Dr. Hou grew up in China, is fluent in Mandarin, and received his B.S. in Chemistry from the University of Science and Technology of China in 1989. He received his Ph.D. in Physical Chemistry from UC Berkeley in 1995 under the guidance of Nobel laureate Professor Yuan T. Lee. He was engaged for four years at the IBM Almaden Research Center as a postdoctoral research fellow.